Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiollabeled, humanized anti-CD22 monoclonal antibody, epratuzumab

Clinical Cancer Research

Volumn 11, Issue 14, 2005, Pages 5215-5222

  Lindén, Ola ^a   Hindorf, Cecilia ^a   Cavallin Ståhl, Eva ^a   Wegener, William A ^b   Goldenberg, David M ^b,c   Horne, Heather ^b   Ohlsson, Tomas ^a   Stenberg, Lars ^a   Strand, Sven Erik ^a   Tennvall, Jan ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b IMMUNOMEDICS INC   (United States)

^c CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; EPRATUZUMAB; INDIUM 111; MONOCLONAL ANTIBODY; YTTRIUM 90;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSIMETRY; DRUG CONJUGATION; DRUG SAFETY; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD22; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CELL ADHESION MOLECULES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INFUSIONS, INTRAVENOUS; LECTINS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 22344437047     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0172     Document Type: Article

References (40)

1. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphome. J Clin Oncol 1999;17: 3793-803.
2. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262-9.
3. Witzig TE, Gordon LI, Cafcanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-63.
4. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002;99:4336-42.
5. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131) I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259-66.
6. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000;18:1316-23.
7. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study pf iodine 1131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19: 3918-28.
8. Wahl RL, Zasadny KR, Estes J, et al. Single center experience with iodine-131 tositumomab radioimmunotherapy for previously untreated follicular lymphoma. In: Society of Nuclear Medicine 47th annual meeting, 2000. J Nucl Med 2000;41:78P.
9. Horning SJ, Lucas A, Younes D, et al. Iodine-131 tositumomab for non-Hodgkin's lymphoma (NHL) patients who progressed after treatment with rituximab: results of a multi-center Phase II study. In: The American Society of Hematology 43rd annual meeting and exposition 2000; 2000. p. 508a.
10. O'Donoghue JA. Dosimetric principles of targeted radiotherapy. In: Abrams PG, Fritzberg AR, editors. Radioimmunotherpy of cancer. New York: Marcel Dekker, Inc.; 2000. p. 1-20.
11. DeNardo GL, Schlom J, Buchsbaum DJ, et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer 2002;94: 1332-48.
12. Schlom J, Molinolo A, Simpson JF, et al. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst 1990;82: 763-71.
13. 131I-Lym-1 antibody. Cancer Biother Radiopharm 1998;13:239-54.
14. 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. Leuk Lymphoma 2000;38:91-101.
15. Leung SO, Goldenberg DM, Dion AS, et al Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Mol Immunol 1995;32: 1413-27.
16. Stein R, Belisle E, Hansen HJ, Goldenberg DM. Epitope specificity of the ami-(B cell lymphoma) monoclonal antibody, LL2. Cancer Immunol Immunother 1993;37:293-8.
17. Shin LB, Lu HH, Xuan H, Goldenberg DM. Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2. Int J Cancer 1994;56:538-45.
18. Cyster JG, Goodnow CC. Tuning antigen receptor signaling by CD22: integrating cues from antigens and the microenvironment. Immunity 1997; 6:509-17.
19. Carnahan J, Wang P, Kendall R, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res 2003;9:3982-903.
20. Leonard JP, Coleman M, Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3051-9.
21. Leonard JP, Coleman M, Ketas JC, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res 2004;10:5327-34.
22. Siegel AB, Goldenberg DM, Cesano A, Coleman M, Leonard JP. CD22-directed monoclonal antibody therapy for lymphoma. Semin Oncol 2003;30:457-64.
23. Emmanoulides C, Leonard JP, Schuster SJ, et al. Multi-center, phase 2 study of combination antibody therapy with epratuzumab plus rituximab in recurring low-grade NHL. Blood 2003;102/11:69a.
24. 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas. Clin Cancer Res 1999;5:3287-91s.
25. Sharkey RM, Behr TM, Mattes MJ, et al. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother 1997;44:179-88.
26. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med 2003;44:77-84.
27. 90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med 2003;44:2000-18.
28. Linden O, Hindorf C, Cavallin-Stahl E, et al. Outcome and absorbed dose following 90-Yttrium-epratuzumab in B-cell lymphoma, using a dose-fractionation schedule. In: American Society of Hematology 45th annual meeting 2003. Blood 2003;102:407a.
29. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993;34:689-94.
30. Fleming A. technique for the measurement of activity using a gamma camera and computer. Phys Med Biol 1979;24:176-80.
31. Loevinger R, Budinger TF, Watson E. MIRD primer for absorbed dose calculations. Revised edition. New York: The Society of Nuclear Medicine: 1991.
32. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-53.
33. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441-9.
34. Sawyer EJ, Timothy AR. Low dose palliative radiotherapy in low grade non-Hodgkin's lymphoma. Radiother Oncol 1997;42:49-51.
35. Britton KE. Radioimmunotherapy of Non-Hodgkin's lymphoma. J Nucl Med 2004;45:924-5.
36. Goldenberg DM, Sharkey RM. Radioimmunotherapy of non-Hodgkin's lymphoma revisited. J Nucl Med 2005;46:383-4.
37. Davis TA, Kaminski MS, Leonard JP, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 2004;10: 7792-8.
38. Hindorf C, Linden O, Stenberg L, Tennvall J, Strand SE. Change in tumor-absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients. Clin Cancer Res 2003; 9:4003-6S.
39. Hartmann Siantar CL, DeNardo GL, DeNardo SJ. Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy. J Nucl Med 2003;44:1322-9.
40. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329:1219-24.